Vanfund(SZ:000638)2020-07-08 16:00Financial Performance - The company's operating revenue for the first quarter of 2020 was CNY 22,904,521.61, representing a 50.51% increase compared to CNY 15,218,371.02 in the same period last year[7]. - The net profit attributable to shareholders of the listed company was a loss of CNY 6,269,305.38, which is a 209.84% increase in loss compared to a loss of CNY 2,023,390.49 in the previous year[7]. - The net loss for Q1 2020 was CNY 10,056,799.43, compared to a net loss of CNY 2,658,843.76 in the same period last year[39]. - Total comprehensive income for the period was also a loss of ¥1,210,590.67, reflecting the same trend as net profit[44]. - Basic and diluted earnings per share for Q1 2020 were both -0.0203, compared to -0.0065 in the previous year[40]. Cash Flow - The net cash flow from operating activities was CNY -10,407,171.63, showing a slight improvement of 1.00% from CNY -10,511,994.70 in the same period last year[7]. - The company’s cash flow from financing activities resulted in a net outflow of ¥437,357.88, compared to a larger outflow of ¥10,615,297.13 in the previous period[48]. - The net cash flow from investment activities was CNY 5,805,900.00, primarily due to the receipt of funds from the transfer of subsidiary equity[15]. - The net cash flow from investment activities amounted to ¥6,000,000 in Q1 2020[51]. - The ending balance of cash and cash equivalents was ¥51,089,625.89, a decrease from the beginning balance of ¥50,297,418.14[51]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 510,447,389.47, a decrease of 3.37% from CNY 528,275,795.87 at the end of the previous year[7]. - The company's total assets amounted to RMB 510,447,389.47, a decrease from RMB 528,275,795.87 on December 31, 2019[29][30]. - The company's total liabilities as of March 31, 2020, were RMB 295,376,442.16, down from RMB 303,148,049.13[31]. - The total liabilities decreased from CNY 226,833,666.38 to CNY 222,614,172.56 during the same period[35]. - The company's equity attributable to the parent company decreased from CNY 150,733,210.98 to CNY 144,463,905.60[34]. Expenses - The total operating costs for the first quarter amounted to CNY 35,741,447.40, which is a 102.76% increase compared to the previous year[14]. - Management expenses increased by 168.48% to CNY 11,059,951.42, primarily due to an increase in management personnel at a subsidiary[14]. - The company reported a significant increase in management expenses, rising from CNY 4,119,497.37 to CNY 11,059,951.42[38]. - Research and development expenses decreased by 62.92% to CNY 1,149,648.98, mainly due to reduced R&D spending at a subsidiary[14]. - Financial expenses totaled ¥150,968.66, a significant decrease from a negative financial expense of ¥1,799,348.81 in the prior period[43]. Shareholder Information - The company had a total of 36,200 common shareholders at the end of the reporting period[10]. - The company agreed to sell a 40% stake in Chengdu Yihuan Medical Technology Co., Ltd. for RMB 47 million (approximately $6.7 million) on September 29, 2019[16]. - The company signed a share transfer agreement on February 12, 2020, to transfer its 40% stake in Yihuan Medical for RMB 47 million[17]. Compliance and Reporting - The company reported no significant non-compliance issues regarding external guarantees during the reporting period[24]. - There were no securities investments or entrusted financial management activities reported during the period[19][20]. - The first quarter report for 2020 was not audited[58]. - The company adopted new revenue and leasing standards starting January 1, 2020, impacting financial reporting[54].